Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
AHG
Akso Health Group
Sale of medical devices and biometrics hardware.
|
$330.74M |
$1.56
+17.29%
|
|
AMRN
Amarin Corporation plc
Amarin's flagship product VASCEPA/icosapent ethyl is a cardiovascular drug indicated to reduce major adverse cardiovascular events when added to statin therapy, making 'Cardiovascular Drugs' a core category.
|
$328.94M |
$16.05
-2.10%
|
|
CLLS
Cellectis S.A.
Lead assets UCART22 and UCART20x22 are allogeneic cell therapies (CAR-T) directly developed and manufactured by the company.
|
$318.95M |
$4.40
-1.79%
|
|
BNTC
Benitec Biopharma Inc.
BB-301 is an AAV-based gene therapy leveraging gene silencing and wildtype replacement, aligning with Gene Therapy.
|
$310.81M |
$11.83
-2.87%
|
|
AARD
Aardvark Therapeutics, Inc. Common Stock
ARD-101 and ARD-201 are oral small-molecule therapeutics targeting satiety pathways for metabolic and rare-disease indications.
|
$309.61M |
$14.20
-2.14%
|
|
NVEC
NVE Corporation
Medical devices & biometrics applications, including implantable sensors and collaboration with Abbott.
|
$308.08M |
$63.89
+0.27%
|
|
PBYI
Puma Biotechnology, Inc.
Direct oncology biotech core product portfolio with Nerlynx and alisertib being cancer therapies.
|
$307.77M |
$6.16
-0.73%
|
|
WW
WW International, Inc.
WW operates WW Clinic and integrated weight health services, including clinical care delivery.
|
$303.90M |
$30.71
-10.79%
|
|
SCPH
scPharmaceuticals Inc.
FUROSCIX is a cardiovascular drug (diuretic) approved for heart failure and CKD, representing SCPH's core product.
|
$299.33M |
$5.67
|
|
DDD
3D Systems Corporation
Offers dental equipment and dental 3D printing solutions (NextDent).
|
$298.83M |
$2.31
-9.96%
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$296.90M |
$23.90
-1.16%
|
|
SENS
Senseonics Holdings, Inc.
Senseonics develops and markets implantable medical devices and biometric sensing technologies (Eversense CGM), fitting the Medical Devices & Biometrics investable theme.
|
$294.10M |
$7.12
-0.07%
|
|
EPRX
Eupraxia Pharmaceuticals Inc.
Diffusphere is Eupraxia's proprietary drug-delivery platform enabling localized, extended-release formulation, a core product/technology they directly develop and apply to its pipeline candidates EP-104IAR and EP-104GI.
|
$291.99M |
$8.13
-5.30%
|
|
FHTX
Foghorn Therapeutics Inc.
Clinical-stage biotech focused on oncology therapies targeting chromatin regulatory system (SMARCA2/BRG1, CBP/EP300, ARID1B degraders), a cancer-focused platform.
|
$291.69M |
$5.17
-1.05%
|
|
CADL
Candel Therapeutics, Inc.
CAN-2409 and CAN-3110 are viral vector-based therapies, aligning with gene therapy.
|
$290.94M |
$5.39
+1.70%
|
|
SMLR
Semler Scientific, Inc.
QuantaFlo is a diagnostic device used to measure arterial blood flow for PAD, directly constituting Diagnostic Equipment.
|
$286.77M |
$19.51
-5.61%
|
|
ACRS
Aclaris Therapeutics, Inc.
Company's focus is on immuno-inflammatory diseases, aligning with Immunology Therapeutics.
|
$286.00M |
$2.65
-0.93%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$285.94M |
$2.29
-3.99%
|
|
LRMR
Larimar Therapeutics, Inc.
Nomlabofusp is a recombinant fusion protein, i.e., a recombinant protein/enzyme therapeutic.
|
$285.02M |
$3.33
-0.89%
|
|
ACHV
Achieve Life Sciences, Inc.
Cytisinicline is an oral small-molecule therapeutic candidate for smoking cessation, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$284.14M |
$5.50
+0.64%
|
|
VMD
Viemed Healthcare, Inc.
Viemed operates as an in-home healthcare provider delivering home health and hospice services.
|
$280.81M |
$7.25
+0.35%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
Enanta is actively developing antiviral small-molecule therapeutics targeting RSV, fitting the Antiviral Small-Molecule Therapeutics theme.
|
$280.26M |
$13.15
-2.16%
|
|
LFCR
Lifecore Biomedical, Inc.
Lifecore is a pure-play CDMO focused on sterile injectable drug development and manufacturing.
|
$279.91M |
$7.57
-2.57%
|
|
AVIR
Atea Pharmaceuticals, Inc.
Atea's lead program comprises antiviral small-molecule therapeutics targeting HCV.
|
$273.78M |
$3.46
-4.29%
|
|
OWLT
Owlet, Inc.
Owlet sells FDA-cleared Medical Devices & Biometrics (Dream Sock and BabySat) with wearable biosensing capabilities.
|
$269.81M |
$15.27
-0.49%
|
|
ZNTL
Zentalis Pharmaceuticals, Inc.
Zentalis is a biotech company focused on oncology therapies, centered on cancer indications with their lead asset azenosertib.
|
$269.79M |
$3.58
+26.23%
|
|
SPOK
Spok Holdings, Inc.
GenA alphanumeric pager represents a medical device hardware line under Medical Devices & Biometrics.
|
$267.48M |
$12.99
-1.44%
|
|
SNWV
SANUWAVE Health, Inc.
SANUWAVE directly manufactures and markets medical devices (UltraMIST and related wound-care technology) and biometrics for patient care.
|
$265.44M |
$31.33
+2.39%
|
|
SY
So-Young International Inc.
So-Young Clinic is a branded network of outpatient aesthetic centers, which is its core revenue driver.
|
$262.21M |
$2.63
+0.96%
|
|
ZURA
Zura Bio Limited
Zura Bio develops immunology therapeutics for autoimmune and inflammatory diseases (Immunology Therapeutics).
|
$261.37M |
$4.01
-0.25%
|
|
KRMD
KORU Medical Systems, Inc.
KRMD's core business is medical devices focused on patient-centric subcutaneous infusion systems (Freedom) and related components.
|
$261.23M |
$5.66
-2.67%
|
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
Lead programs are oral small-molecule therapeutics targeting NI&I indications.
|
$261.07M |
$9.26
+0.98%
|
|
ABEO
Abeona Therapeutics Inc.
ZEVASKYN is an autologous cell-based therapy (cell therapy) targeting RDEB wounds.
|
$260.49M |
$5.05
-0.49%
|
|
SLN
Silence Therapeutics plc
Silence Therapeutics directly develops RNA interference therapeutics (siRNA) as its core product modality.
|
$260.47M |
$5.50
-5.17%
|
|
NAUT
Nautilus Biotechnology, Inc.
The hardware/assay suite functions as diagnostic-type equipment for proteomics analyses.
|
$260.19M |
$2.06
-6.98%
|
|
HBB
Hamilton Beach Brands Holding Company
Medical devices & biometrics appropriate to HealthBeacon’s connected health offering.
|
$259.15M |
$18.68
+10.34%
|
Showing page 20 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
